In a retrospective cohort study using a 20% Medicare sample from 2007 to 2011, Sosa and colleagues observed that 74% of breast cancer patients and 62% of NHL patients receiving high FN risk chemotherapy received prophylactic G-CSF in the first cycle [25]. The gene discussed is CSF3; the disease is non-Hodgkin lymphoma.